HIV antibody monotherapy trial seeks virus suppression without daily pills
NCT ID NCT02355184
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study tested whether a monoclonal antibody called PRO 140 could keep HIV under control when used alone, replacing standard combination antiretroviral therapy (ART). Twenty adults with HIV who had completed a prior study without virus rebound were enrolled. The main goal was to measure how long it took for the virus to return after switching to PRO 140 alone. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CD01-Extension Investigational Site
San Francisco, California, 94115, United States
Conditions
Explore the condition pages connected to this study.